14 Section A - Justification_Extension Request 03-02-01

14 Section A - Justification_Extension Request 03-02-01.docx

Formative Research to Develop Social Marketing Campaigns-Routine HIV Testing For Emergency Medicine Physicians, Prevention Is Care, and Partner Services

OMB: 0920-0775

Document [docx]
Download: docx | pdf

Supporting Statement A




OMB control # 0920-0775




Formative Research to Develop Social Marketing Campaigns- Routine HIV Testing for Emergency Medicine Physicians, Prevention Is Care, and Partner Services
















March 1, 2011





Project officer:

Donata R. Green, Ph.D.
Centers for Disease Control and Prevention
Division of HIV/AIDS Prevention
8 Corporate Blvd.
Mail Stop E-49, Room 5020
Atlanta, GA 30329
(404) 639-3869 office
(404) 639-2007 fax

dqg7@cdc.gov


TABLE OF Contents


Section



B. Collection of Information Involving statistical Methods

1. Respondent Universe and Sampling Methods

2. Procedures for the Collection of Information

3. Methods to Maximize Response Rates and Deal with Nonresponse

4. Test of Procedures or Methods to Be Undertaken

5. Individuals Consulted on Statistical Aspects and Individuals Collecting and/or Analyzing Data

References


Exhibits


Exhibit 8.1 Individuals Consulted During theDevelopment of Routine HIV Testing Campaign

Exhibit 8.2 Individuals Consulted During the Development of the PIC Campaign

Exhibit 12.1Estimated Annualized Burden Hours

Exhibit 12.2Estimated Annualized Burden Costs

Exhibit 14.1Estimated Cost to the Government

Exhibit 16.1Project Time Schedule




LIST OF ATTACHMENTS


1.Authorizing Legislation and Other Relevant Laws

2(a).Data Collection Instruments – Routine HIV Testing in Emergency Departments

2(b). Data Collection Instruments – Prevention is Care (PIC)

2(c). Data Collection Instruments – HIV Partner Services (Concept Testing)

2(d). Data Collection Instruments – HIV Partner Services (Materials Testing)

3(a).Federal Register Notices to the Public (30-day)

3(b).Federal Register Notices to the Public (60-day)

4.Institutional Review Board (IRB) Approval

5(a).Consent Forms – Routine HIV Testing in Emergency Departments

5(b).Consent Forms – Prevention is Care (PIC)

5(c).Consent Forms – HIV Partner Services

6(a).Study Screening Instruments – Routine HIV Testing in Emergency Departments

6(b).Study Screening Instruments – Prevention is Care (PIC)

6(c).Study Screening Instruments – HIV Partner Services

7(a).Paper and Pencil Survey – Routine HIV Testing in Emergency Departments

7(b).Paper and Pencil Survey – Prevention is Care (PIC)

7(c).Paper and Pencil Survey – HIV Partner Services

8. Privacy Agreement

Formative Research to Develop Social Marketing Campaigns- Routine HIV Testing for Emergency Medicine Physicians, Prevention Is Care, and Partner Services


A. Justification

1. Circumstances Making the Collection of Information Necessary

The Centers for Disease Control and Prevention (CDC), Division of HIV/AIDS Prevention, requests a time extension for OMB 0920-0775 to continue a formative research study to support CDC’s efforts in further developing three social marketing campaigns targeting infectious disease specialists, primary care physicians, and emergency department physicians. The campaigns of focus remain the same: Routine HIV Testing, Prevention is Care (PIC) and Partner Services. To date, we have conducted a total of 162 interviews and have 82 remaining interviews to conduct. All exploratory research has been completed. The remaining interviews will be to finish creating materials for the three campaigns. The remaining interviews from 0920-0775 were not conducted due to budget reductions and eliminations. Therefore all materials were not developed. The materials to be tested will supplement the existing materials developed from the 162 interviews and will contain updated surveillance data, continue to promote CDC’s 2006 Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings among physicians in private practice and emergency departments and promote the new recommendations, if released in time. These materials will be used by the target audience to assist them with offering and conducting HIV prevention and testing. The remaining interviews are necessary to finish creating all of the materials and ensure the new materials are appropriate for the target audience.

Historically, prevention efforts have targeted people at risk for HIV infection with the goal of keeping those who are HIV negative from becoming infected. However, the epidemic has changed with the introduction of highly active anti-retroviral therapy. Despite advances in treatment and numerous prevention efforts, HIV continues to spread with an estimated 56,000 new HIV infections annually (Hall et al., 2008). An estimated 1.1 million Americans are living with HIV, and 1 out of 5 people with HIV do not know they have it (CDC, 2008). CDC’s goal, since 2001, has been to reduce the number of new HIV infections in the United States from an estimated 56,000 to 20,000 per year, focusing particularly on eliminating racial and ethnic disparities in new HIV infections.

Healthy People 2010 and 2020 objectives focus on preventing HIV infection and its related illness and death. In particular, Healthy People 2010 aimed to reduce the number of new cases of HIV/AIDS diagnosed among adult and adolescents and to increase the proportion of HIV-infected persons who know they are infected. Healthy People 2020 includes these objectives, as well as a new objective aiming to increase the proportion of adults and adolescents who have been tested for HIV in the past 12 months.

In 2010, the Office of National AIDS Policy out of the White House developed the National HIV/AIDS Strategy (NHAS) with three primary goals: 1) reducing the number of people who become infected with HIV; 2) increasing access to care and improving health outcomes for people living with HIV; and, 3) reducing HIV-related health disparities. In support of Healthy People 2010 and 2020 and the NHAS, CDC will finish developing all materials for the three campaigns targeting health care providers:

  • Routine HIV Testing: The goal of this campaign is to increase HIV testing rates among those seeking emergency care services and those who may use emergency services to deliver their primary medical care needs. Those with a lower socioeconomic status (SES) are less likely to receive preventive care from primary care physicians (PCPs) or other health care providers outside emergency department settings, thus missing the opportunity for routine HIV screening. Research has found that persons with a lower SES often attend emergency departments for primary health care services (Alpert et al. 1996). Therefore, an emergency medicine physician has a unique opportunity to provide HIV screening services that a patient would otherwise not receive, or to counsel a patient to seek HIV testing.

  • Prevention Is Care (PIC): PIC seeks to encourage Infectious Disease Specialists (IDS) and Primary Care Providers (PCPs) to screen their patients living with HIV for potential HIV transmission behaviors and deliver brief messages on the importance of protecting themselves and others by reducing their risky behaviors. Therefore, the goal of this campaign is to establish PIC as the standard of care for persons living with HIV.

  • Partner Services: The goal of this campaign is to incorporate Partner Services into the care for persons diagnosed with HIV. Partner Services are a set of activities led by State Health Departments, and supported by healthcare providers, to notify the sex and drug-injection partners of HIV-positive persons that they have been exposed to HIV; offer them counseling, testing and referral services; and ensure that all HIV-positive persons are linked to appropriate medical care.

The following section of the U.S. Federal Code (see Attachment 1) is relevant to this data collection: 42 USC 241, Section 301 of the Public Health Service Act authorizes conduct of “research, investigations, experiments, demonstrations, and studies relating to the causes, diagnosis, treatment, control, and prevention of physical and mental diseases and impairments of man.”

2. Purpose and Use of the Information Collection

The purpose of this study is to continue one time semi structured in person in-depth interviews to finish developing all of the materials for the three social marketing campaigns (Routine HIV Testing, PIC, and Partner Services). RTI International, the evaluation contractor, will conduct the interviews and will interview each physician only once in order to finish developing all new campaign materials. We will continue to gain an understanding and identify physicians’:

    • Current practices (e.g., HIV testing, behavioral screening, partner notification and referral)

    • Use of HIV prevention and education materials with patients

    • Perceived and actual barriers to implementing new guidelines/recommendations

    • Initial reactions to campaign materials (e.g., visual appeal, format, design, content, usefulness, credibility)

    • Preferred channels for obtaining new information on guidelines or practices

    • Interest in provider resources and patient educational materials

The three social marketing campaigns will continue to increase the adoption of CDC’s 2006 Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings among physicians in private practice and emergency departments and the new recommendations, if released in time. All data collection instruments will remain the same, see Attachment 2 for the data collection instruments. We will disseminate the final study results to the public once all formative research has been completed. The reports will be prepared for and/or by CDC or RTI and will be submitted to peer-reviewed journals where appropriate. All releases of information will be reviewed and approved by CDC.

3. Use of Improved Information Technology and Burden Reduction

The data collection requires that we continue to employ qualitative research methods through the use of one time in person in-depth interviews. The responses from the participants are as important as the interviewers’ observation of the participant and the overall interview. Where possible and upon consent from the participant, we will audio tape the interviews to capture all information and assist with preparation of reports.

4. Efforts to Identify Duplication and Use of Similar Information

In order to identify duplication and use of similar information, we conducted a review of the literature to update the existing literature review results. We continued to examine several large periodical journal databases and “gray” literature by exploring the Internet. Searches were performed on several Internet search engines, including Google, Yahoo, AltaVista, Medline, and Science Direct. We were unable to find duplication or the use of similar information. Therefore, we have confirmed the need to continue developing materials for the present study.

5. Impact on Small Businesses or Other Small Entities

This study does not have impact on small businesses or other small entities. We will schedule all interviews at the convenience of the physician and we will not impact the physicians practice.

6. Consequences of Collecting the Information Less Frequently

This is an ad hoc data collection (i.e., a one-time study to develop three social marketing campaigns and does not require periodic collection of data). There are no legal obstacles to reduce burden. The present study will continue to provide data needed to develop additional materials for the Routine Testing, PIC, and Partner Services campaign materials. If we did not conduct this formative research, we would not be able to pre-test the additional campaign materials with the target audiences before they are widely distributed. Our formative research process includes gaining an understanding of a target audience’s perceived needs, benefits sought, and barriers of concern. Subsequently, materials are developed that are responsive to the target audience’s perspectives, needs, and concerns. We then test the materials with members of the target audience before they are widely disseminated (Slater, 1995). This project is critically important because it involves testing the additional materials that are being developed as part of the three social marketing campaigns described above.

7. Special Circumstances Relating to the Guidelines of 5 CFR 1320.5

There are no other special circumstances that require the data collection to be conducted in a manner inconsistent with 5 CRF 1320.5 (d)(2). This data collection request fully complies with the regulation.

8. Comments in Response to the Federal Register Notice and Efforts to Consult Outside the Agency

A. A 60-Day Federal Register notice for Formative Research to Develop the Routine HIV Testing for Emergency Medicine Physicians, Prevention Is Care (PIC), and Partner Services Social Marketing Campaigns—Extension— (0920–0775, exp. 4/30/2011) was published on December 3, 2010 (Volume 75, Number 232, pages 74574) and solicited comments. No comments were received. A copy of the 30 day and 60-day Federal Register notices can be found as Attachments 3a and 3b respectively.

B. The CDC study team collaborated with RTI International staff (evaluation contractor) on the study design, screening instruments, and interview guides. RTI staff is trained and experienced in formative research. CDC recognizes the importance of gaining valuable insights directly from members of the target audience and from organizations and individuals who work with them in the community. Consultation with individuals and related activities occurred for each campaign at various times in 2005 and 2006. Additional consultations occurred in 2010. All individuals consulted are listed below. No major problems were identified that could not be resolved.

At various points in 2005, 2006, 2009 and 2010 we consulted with the following individuals for development of the campaigns’ concepts, messages, and materials. Some materials have already been developed based on the 2005 and 2006 consultations and the formative research conducted in those years. In 2009 and 2010 we consulted with additional individuals for continued program direction and development of the remaining materials to be tested under this extension. See Exhibits 8.1 and 8.2 for individuals consulted by campaign in 2005, 2006, 2009 and 2010. We will continue to consult the individuals listed below as needed.

Exhibit 8.1. Individuals Consulted During the Development of Routine HIV Testing and Campaign


2005-2006 Individuals Consulted

Bernard M Branson, M.D.

Associate Director for Laboratory Diagnostics

Divisions of HIV/AIDS Prevention

National Center for HIV, STD and TB Prevention

Centers for Disease Control and Prevention

1600 Clifton Road

Atlanta, GA 30333

(404) 639-6166

BBranson@cdc.gov

Margaret Lampe, RN, MPH

Acting Team Lead, EPI Branch

Divisions of HIV/AIDS Prevention

National Center for HIV, STD and TB Prevention

Centers for Disease Control and Prevention

1600 Clifton Road

Atlanta, GA 30333

(404) 639-5189

MLampe@cdc.gov


2009-2010 Individuals Consulted

Amir Qaseem, MD, PhD

Senior Medical Associate in the Clinical Program and Quality of Care Department of Medical Education and Publishing Division

American College of Physicians

190 North Independence Mall West

Philadelphia, PA 19106-1572

215-503-8575

Aqaseem@mail.acponline.org

Celia J. Maxwell, MD, FACP

Assistant Vice President for Health Sciences

Director of Women’s Health Institute

Howard University

1315 Leegate Road NW

Washington, DC 20012

202-865-7513

cmaxwell@howard.edu


Donna E. Sweet, MD, MACP

Professor of Medicine

The University of Kansas School of Medicine – Wichita

1010 N. Kansas

Wichita, Kansas 67214

316-268-5984

dsweet@kumc.edu

Jeffrey T. Kirchner, DO, AAHIVS

Medical Director of Comprehensive Care Center for HIV, Lancaster General Hospital

LGH Family & Community Medicine

555 North Duke Street,

PO Box 3555

Lancaster, PA 17604

717-544-4940

JTKirchn@LancasterGeneral.org


Jim Sosman, MD

Associate Director, HIV Care Program Associate Professor of Medicine, University of Wisconsin School of Medicine and Public Health

2828 Marshall Court, Suite 100

Madison, WI 53705

608-263-5259

Jms@medicine.wisc.edu


Joel Gallant, MD, MPH

Associate Director,

Johns Hopkins AIDS Service

1830 E. Monument Street

Room 443

Baltimore, MD 21205

410-955-7473

jgallant@jhmi.edu


Joseph McGowan, MD, FACP

Medical Director, NYS Designated AIDS Center

North Shore University Hospital 16 Country Club Lane

Briarcliff Manor, NY 10510

516-562-4280

JMcGowan@NSHS.edu


Lynn E. Sullivan, MD Assistant Professor of Medicine, Department of Internal Medicine, Yale University

367 Cedar Street

PO Box 208093

New Haven, CT 06520-8093

203-688-9105

lynn.sullivan@yale.edu


Margaret Hoffman-Terry, MD, AAHIVS

Chief of HIV Medicine

Lehigh Valley Hospital

413 N. Jasper St.

Allentown, PA 18109

610-969-2400

mhtc70@aol.com


Ron Goldschmidt, MD

Director, National HIV/AIDS Clinicians' Consultation Center (NCCC)Professor of Clinical Family and Community Medicine, Vice-Chair, UCSF Department of Family and Community Medicine

San Francisco General Hospital

1001 Potrero Avenue,

Building 80-83

San Francisco, CA 94110

415-206-5792

rgoldschmidt@nccc.ucsf.edu


Ronald Lubelchek, MD

Attending Physician

Division of Infectious Diseases

John H. Stroger Hospital of Cook County

1372 N. Dean Street, Apt. 1

Chicago, IL 60622

312-864-4590

rlubel@gmail.com


Wilbert Jordan, MD, MPH

Medical Director, Oasis Clinic

1807 E. 120th St.

Los Angeles, CA 90059

310-668-4213

tojo44@aol.com


Richard Rothman, MD, PhD

Johns Hopkins Department of Emergency Medicine5801 Smith Avenue, Suite 3220Davis Building

Baltimore, MD, 21209

410-735-6428

rrothman@jhmi.edu


Michael S. Lyons, MD,MPH Assistant Professor Department of Emergency Medicine University of Cincinnati College of Medicine

513-558-8629

lyonsme@ucmail.uc.edu




Exhibit 8.2. Individuals Consulted During the Development of the PIC Campaign


2005-2006 Individuals Consulted

Bernard M Branson, M.D.

Associate Director for Laboratory Diagnostics

Divisions of HIV/AIDS Prevention

National Center for HIV, STD and TB Prevention

Centers for Disease Control and Prevention

1600 Clifton Road

Atlanta, GA 30333

(404) 639-6166

BBranson@cdc.gov

Mark Thrun, M.D.—Medical Director, Denver STD/HIV Prevention Training Center

605 Bannock Street, MC 2600

Denver, CO 80204

(303) 436-7071

Mark.Thrun@dhha.org

Judith Absalon, M.D., MPH—Assistant Professor of Epidemiology, Mailman School of Public Health, Columbia University

722 West 168th St, Room 513

New York, NY 10032

(212) 342-0533

ja234@columbia.edu

Howard Grossman, M.D.—Executive Director, American Academy of HIV Medicine

1705 DeSales Street, Suite 700

Washington, DC 20036

(877) 422-4486

howard@aahivm.org

Wayne Bockmon, M.D.—Staff Physician, Montrose Clinic

4706 Westslope Circle

Austin, TX 78731

(512) 420-2314

kwb@austin.rr.com

Peter Meacher, M.D.—Medical Director, South Bronx Health Center for Children and Families, Montefiore Medical Center

871 Prospect Avenue

Bronx, NY 10459

(718) 991.0605 x 236

pmeacher@montefiore.org

Alwyn Cohall, M.D.—Associate Professor, Harlem Health Promotion Center, Mailman School of Public Health, Columbia University

215 West 125th Street
New York, NY 10027
(646) 284-9725
atc1@columbia.edu

Peter Shalit, M.D., Ph.D.—Physician, Swedish Medical Center

1120 Cherry Street, #320

Seattle, WA 98104

(206) 624-0688

psmd@mac.com

Donald T. Evans, M.D.—Physician, Founder, AIDS Project Greater Danbury

115 Mount Pleasant Rd.

Newton, CT

(203) 426-5626

apgd99@aol.com



2009-2010 Individuals Consulted

John Bartlett

Chief, Professor of Medicine

Division of Infectious Diseases Johns Hopkins University School of Medicine

1830 E. Monument St.

RM 439

Baltimore, MD 21205

410.955.7634

jb@jhmi.edu


Constance Benson

Professor of Medicine

UCSD Antiviral Research Center Department of Medicine

Mail Code 8208150 West Washington Street, Suite 100

San Diego, CA 92103

(619) 543-8080

cbenson@ucsd.edu


Wayne Bockmon

Practicing Physician

Montrose Clinic

4706 Westslope Circle

Austin, TX 78731

512.420.2314 (Home)512.350.6911 (Cell)

kwb123@gmail.com


John Brooks

Leader, Clinical Epidemiology Team

Division of HIV/AIDS Prevention, NCHSTP

Centers for Disease Control and Prevention1600 Clifton Rd., MS E-45

Atlanta, GA 30333

404.639.3894

zud4@cdc.gov


Kevin Charmichael

Chief of Service

El Rio Special Immunology Associates1701 W. St. Mary's Road, Suite 160

Tuscon, AZ 85745

520.628.8287

kevinc@elrio.org

jkcsia@elrio.org


Alwyn Cohall

Associate Professor of Clinical Public Health and Clinical Pediatrics

Mailman School of Public Health of Columbia University

215 West 125th St., Ground Floor

New York, NY 10027

646.284.9725

atc1@columbia.edu


Eric Daar

Director of the Division of HIV Medicine

Harbor-UCLA Medical Center, Box 400

1000 W. Carson Street

Torrence, CA 90509

310.222.2401

edaar@labiomed.org


David Hardy

Associate Professor of Medicine

Cedars-Sinai Medical Center Infectious Diseases

8700 Beverly Bl, #B-220

Los Angeles, CA 90048

310.423.3896

david.hardy@cshs.org


Peter Meacher

Practicing Physician

South Bronx Health Center for Children and Families

Montefiore Medical Center

871 Prospect Ave.

Bronx, NY 10459

718.991.0605 x 236

pmeacher@montefiore.org


Evelyn Quinlivan

Assistant Professor of Medicine

Director, Infectious Diseases Clinic

School of Medicine

The University of North Carolina at Chapel Hill

Bioinformatics Building

130 Mason Farm Road

Campus Box 7030

Chapel Hill, NC 27599

919.966.2536

ebq@med.unc.edu


Peter Shalit

Practicing Physician Swedish Medical Center

1120 Cherry Street, #320

Seattle, WA 98104

206.624.0688

psmd@mac.com



Mark Thrun

Medical Director, HIV Prevention

Denver STD/HIV Prevention Training Center

605 Bannock Street, MC 2600

Denver, CO 80204

303.436.7071

303.602.3645 (NEW)

Mark.Thrun@dhha.org


Kimberly Smith

Rush University Medical Center

600 S. Paulina Street, Suite 143

Chicago, Illinois,60612

312-942-5865

Kimberly_Y_Smith@rush.edu


Kathleen E. Squires

1339 Chestnut St.

Philadelphia, PA 19107

215-627-0321

Kathleen.Squires@jefferson.edu




In addition, we will continue to consult with representatives from state health departments on an ongoing basis throughout the campaign development process to ensure that their perspectives are incorporated into the development of the campaign materials.

9. Explanation of Any Payment or Gift to Respondents

We will give all participants a token of our appreciation.

Emergency medicine physician interview $200

PCP interview $150

IDS interview $250



The tokens of appreciation were determined based upon the burden to the participants, taking into account that the participants are physicians, the length of the interview, the fact that participants may have to travel a considerable distance to and from the focus group facility, parking costs, and our previous experience conducting interviews with PCPs and IDS. This is intended to recognize the time burden placed on the participants, encourage their cooperation, and to convey appreciation for contributing to this important study. Numerous empirical studies have shown that honoraria can significantly increase response rates (e.g., Abreu & Winters, 1999; Shettle & Mooney, 1999; Greenbaum, 2000). Physicians are a difficult population to reach because they are highly paid and their time is at a premium. They are frequently bombarded by numerous entities all requesting their time for interviews, surveys and pharmaceutical sales presentations. As a result, they often decline to participate.


Our experience has shown that a smaller token of appreciation does not appear sufficiently attractive to physicians especially given that a higher number of physicians are now paid on a fee-for-service basis, and may be reluctant to leave their office for an interview. For example, if a physician sees a minimum of four patients an hour, each with an average billing rate of $50, this equates to a physician hourly rate of $200 without leaving the office. Suggested standard rates range from $200 to $250 for physicians (Slaughter, et. al, 1999). This amount is consistent with quotes RTI received in 2006 from focus group facilities for recruiting PCPs and IDS. Higher amounts may be necessary to recruit physicians who see a higher number of patients per hour or who have additional years of specialized training, such as IDS. We also believe that the token of appreciation will result in higher data validity as physicians become more engaged in the interview process. Participants will receive their token of appreciation immediately after completing their participation in the interview.



10. Assurance of Confidentiality Provided to Respondents

This data collection has received NCHHSTP Project Determination approval as a part of a larger project determination focusing on medical providers. See Attachment 4.

In review of this application, it has been determined that the Privacy Act is not applicable.

The contractor RTI will utilize names and addresses to send reminder letters/e-mails and make reminder phone calls, but the information will not be recorded on the actual surveys. All questionable data and the personal identifiers needed to locate potential participants will be stored in separate locked file cabinets in locked offices in a secured facility. All electronic files will be password controlled and only accessible to fully authorized personnel and maintained and protect to the extent allowed by law.

RTI will select and reserve focus group facilities in each city for each of the three campaigns, overseeing the local focus group facilities’ recruitment of participants. Recruitment staff will receive extensive instruction on the importance of maintaining data in a secure manner at all times. Furthermore all employees who work on this study will be required to sign a Privacy Agreement (Attachment 8). RTI and the focus group facilities will use screening instruments to identify eligible participants for the study. As participants are recruited, recruitment grids will be prepared to keep track of the recruitment, listing the participants’ first name and some demographic obtained from the screener. The recruitment grid will be stored in a locked file cabinet or on a password protected project share drive at RTI, each focus group facility will destroy their copy of the recruitment grid after data collection has been completed. Copies of the recruitment grid will be provided to RTI and CDC for description of the study sample, which will be kept in locked file cabinets or on a password protected project share drive at RTI and CDC for the duration of the study.

No identifying information will be kept at the focus group facilities after the interviews are completed and the focus group facilities will not send any identifying information to RTI or CDC.

Once the potential participant comes to the study site and checks in, he/she will be given a consent form. The individual will be given time to read the consent form on his/her own and a trained RTI staff member will be available to answer any questions. If the participant agrees to be in the study, he/she will sign the consent form and be given a copy to keep for his/her records. Participants will be reminded that they can refuse to answer any question and they can stop being in the study at any time, without penalty. RTI staff will FedEx or personally take these forms back to RTI after the interviews are completed in each city. The consent forms will be stored in a locked file cabinet at RTI for the duration of the project. Once the project ends, the forms will be transferred to a locked RTI storage facility for three years. After three years, RTI staff will destroy the forms.

11. Justification for Sensitive Questions

Sensitive information will not be collected as part of this study.

12. Estimates of Annualized Burden Hours and Costs

The total annualized response burden is estimated at 115 hours. There is no change to the estimated total annualized response burden hours or cost as a result of the extension request. Exhibits 12.1 and 12.2 provide details about how this estimate was calculated. Timings were conducted during our instrument development process to determine the overall burden per respondent. Administration of the screening instrument is estimated to take 10 minutes. Participation in an interview is estimated to take 1 hour. Each year we will complete 123 screening questionnaires (20 hours) and 82 physicians will participate in an interview (82 hours), and take a 10 minute paper and pencil survey (13 hours) totaling 115 hours. Each participant will also complete a 5 minute consent form (7 hours).

Exhibit 12.1. Estimated Annualized Burden Hours





Type of Respondent

Form Name

No. of Respondents

Responses Per Respondent

Average Burden Per Response (in hours)

Total Burden Hours

Emergency Medicine Physicians

Routine HIV Testing Screener

12

1

10/60

2

Routine HIV Testing Interview

8

1

1

8

Routine HIV Testing Paper & Pencil Survey

8

1

10/60

1

Prevention Is Care

PIC Screener

72

1

10/60

12

PIC Interview

48

1

1

48

PIC Paper & Pencil Survey

48

1

10/60

8

Partner Services

Partner Services Screener

39

1

10/60

6

Interview

(Concept Testing)

13

1

1

13

Interview

(Materials Testing)

13

1

1

13

Partner Services Paper & Pencil Survey

26

1

10/60

4


Total




115



In calculating the burden, we used the amount of $66.79 per hour as an estimate of the average physician’s hourly wage rate. We will continue to use the mean hourly wage for physicians and surgeons released from the United States Department of Labor, Bureau of Labor Statistics (May, 2005). Available online at: http://www.bls.gov/oes/current/oes291069.htm. Actual hourly wage rates will vary by physician credentials (e.g., wage rates for IDS may be higher than the wage rates for PCPs). The estimated annual cost to participants for the hour burden for collections of information will be $7,757.00.


Exhibit 12.2 Estimated Annualized Burden Costs

Respondents

Activity

No. of Respondents

No. of Response per Respondent

Average Burden per Response

(in Hours)

Total Burden Hours

Hourly Wage Rate*

Total
Respondent Costs**

Routine HIV Testing in Emergency Departments


Screener

12

1

10/60

2

$66.79

$134

Interview

(Material Testing)

8

1

1

8

$66.79

$534

Paper and Pencil Survey

8

1

10/60

1

$66.79

$89

Prevention Is Care (PIC)

Screener

72

1

10/60

12

$66.79

$801

Interview

(MaterialTesting)

48

1

1

48

$66.79

$3,206

Paper and Pencil Survey

48

1

10/60

8

$66.79

$534

HIV Partner Services

Screener

39

1

10/60

6

$66.79

$434

Interview

(Concept Testing)

13

1

1

13

$66.79

$868

Interview

(Material Testing)

13

1

1

13

$66.79

$868

Paper and Pencil Survey

26

1

10/60

4

$66.79

$289

Total





115


$7,757

13. Estimates of Other Total Annual Cost Burden to Respondents and Record Keepers

Respondents participate on a purely voluntary basis and, therefore, are subject to no direct costs other than their time to participate; there are no start-up or maintenance costs. We do not require any additional record keeping.

14. Annualized Cost to the Government

The total annualized cost for the remainder of this study is estimated to be $293,652. This includes the CDC FTEs and a contractor (see Exhibit 14.1). Details of the annualized costs are contractor’s costs are based on estimates provided by the contractor who will carry out the data collection activities. This is the cost estimated by the contractor, RTI, and includes the estimated cost of coordination with the CDC, data collection, analysis, and reporting.


Exhibit 14.1. Estimated Cost to the Government

Expense Type

Expense Explanation

Annual Costs (dollars)

Direct Cost to the Federal Government

  • CDC oversight of contractor and project

CDC Project Officer

$60,521


CDC Co-Principal Investigator

$59,295

Subtotal, Direct Costs to the Government

$119,816

Contractor and Other Expenses

  • Recruitment and Data Collection (Contractor)

Labor hours and Other Direct Costs

$130,380

  • Analysis and Reporting (Contractor)

Labor hours and ODCs

$43,456

Subtotal, Contracted Services

$173,836

TOTAL COST TO THE COVERNMENT

$293,652





15. Explanation for Program Changes or Adjustments

This is a request for a three year time extension. There is no change in burden requested or associated costs. The remaining interviews will be conducted to finish creating materials for the three campaigns. The remaining interviews from 0920-0775 were not conducted due to budget reductions and eliminations. Therefore all materials were not developed.

16. Plans for Tabulation and Publication and Project Time Schedule

Data from the interviews will be entered into an electronic data matrix by the RTI note taker during the data collection and stored on a password protected computer. Analysis of the interview data will start immediately after completion of data collection in each city and will be conducted under the supervision of a senior staff member with extensive experience in qualitative research. RTI will conduct thematic or ground theory analysis of the data to understand participants’ reactions to the campaign messages in as rigorous and detailed manner as possible. RTI and CDC will review the preliminary data within one week after data collection is completed in each city via a debriefing conference call. RTI analysts will further analyze the data in the matrices and summarize results in three separate topline reports by phase and one final report. Data from the paper and pencil questionnaires will be keyed into Microsoft Excel and be reported in descriptive data tables with accompanying narrative in the topline and summary reports. The key events and reports to be prepared are listed in Exhibit 16.1.

Exhibit 16.1. Project Time Schedule

Activity

Time Schedule

Identify and reserve focus group facilities

1 month after OMB approval

Begin recruitment

1 month after OMB approval

Phase 1: Conduct interviews

2 months after OMB approval

Phase 1: Topline report due

4 months after OMB approval

Phase 2: Conduct interviews

17 months after OMB approval

Phase 2: Topline report due

19 months after OMB approval

Phase 3: Conduct interviews

32 months after OMB approval

Phase 3: Topline report due

34 months after OMB approval

Summary report due

35 months after OMB approval



17. Reason(s) Display of OMB Expiration Date is Inappropriate

We do not seek approval to eliminate the expiration date.

18. Exceptions to Certification for Paperwork Reduction Act Submissions

There are no exceptions to the certification statement.


File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
File TitleSupporting Statement for Paperwork Reduction Act Submission
AuthorPeyton Williams
File Modified0000-00-00
File Created2021-02-01

© 2024 OMB.report | Privacy Policy